Solid Biosciences Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 6.39 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 685.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Details
| Name | Solid Biosciences Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 121 |
| Founded | 2013 |
| Ipo Date | 2018-01-26 |
| Ceo | Alexander Cumbo |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US83422E2046 |
| Cusip | 83422E204 |
| Cik | 0001707502 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer and Director |
| Alexander G. Cumbo | President, Chief Executive Officer and Director |
| Ian F. Smith A.C.A., C.P.A. | Executive Chair |
| David Tyronne Howton Jr., J.D. | Chief Operating Officer and Secretary |
| Dr. Gabriel Brooks M.D. | Chief Medical Officer |
| Annie Ganot | Co-Founder and Vice President of Patient Advocacy |
| Kevin Tan C.F.A. | Chief Financial Officer and Treasurer |
| Paul Herzich | Chief Technology Officer |
| Nicole Anderson | Senior Director of Investor Relations and Corporate Communications |
| Dr. Jessie Hanrahan Ph.D. | Chief Regulatory and Preclinical Operations Officer |
Contact
| Address | 500 Rutherford Avenue, Third Floor, Charlestown, Massachusetts 02129, United States |
| Phone | 617 337 4680 |
| Website | https://www.solidbio.com |